Dialectical Behavioral Therapy As A Therapeutic Tool In Patients With Binge Eating Disorder
Key facts
- Who runs it
- Alexandria University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 60 people enrolled
- Started
- 15 Mar 2023
- Ended
- 15 Sept 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- DBT
- TAU
- Plasma Ghrelin
- Record updated
- 29 January 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Age above 18 years
- Patients diagnosed as BED according to the Diagnostic and Statistical Manual of Mental Disorders- Fifth Version (DSM-5), after providing a written informed consent
- Overweight or obese patients (body mass index ≥ 25), or patients with a history of overweight or obesity
Who cannot take part
- Patients with known psychotic disorders or substance use disorders
- Patients diagnosed with current major depressive or anxiety disorders
- Patients diagnosed with borderline personality disorder
- Patients with medical conditions that can affect or alter the frequency of eating and metabolism (e.g., Thyroid disorders, Diabetes Mellitus, Malignancy)
- Patients who are actively suicidal
- Patients presenting with medical complications of BED
- The presence of purging or compensatory behaviors
- Current pregnancy or breastfeeding
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Binge eating disorder (BED) is one of the recently acknowledged eating disorders, with many theories underlying its pathology whether biological or psychological. From the biological perspective, changes in plasma ghrelin were hypothesized to have a major role in developing and maintaining the disorder, while from the psychopathological perspectives, abnormalities in emotion regulation were found in many patients.
Read full original descriptionShow less
Since Dialectical Behavioral Therapy (DBT) is known to target emotion dysregulation, the main aim of this study is to assess the efficacy of DBT versus treatment as usual (TAU) in BED patients, and whether plasma ghrelin level will be affected after treatment in both arms.
The 2 groups in the trial
- DBT (Group A)Treatment being tested
DBT to be applied over 20 weeks
Treatment: DBT and Plasma Ghrelin
- TAU (Group B)Existing treatment, for comparison
TAU to be applied over 20 weeks
Treatment: TAU and Plasma Ghrelin
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Record updated
- 29 January 2025